<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03367871</url>
  </required_header>
  <id_info>
    <org_study_id>20170846</org_study_id>
    <nct_id>NCT03367871</nct_id>
  </id_info>
  <brief_title>Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer</brief_title>
  <official_title>Phase II Single Arm Study of Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent, or Metastatic Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose to evaluate the efficacy of the combination of standard&#xD;
      chemotherapy with bevacizumab with Pembrolizumab in women with recurrent, persistent, or&#xD;
      metastatic cervical cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 6, 2018</start_date>
  <completion_date type="Anticipated">October 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Objective response defined as the proportion of patients showing complete or partial response to study therapy. Response to therapy will be evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Rate of Progression-Free Survival (PFS) in study participants. PFS is defined as the time from start of treatment until documented disease progression or death (by any cause, in the absence of progression). In alive, progression-free patients, PFS will be censored at the last evaluable tumor assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Rate of Overall Survival (OS) in study participants. OS is defined as the time from start of treatment until death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Experiencing Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>The safety and tolerability profile of the study therapy will be determined by the proportion of study participants experiencing treatment-related adverse events (AEs) and serious adverse events (SAEs). Treatment-related AEs and SAEs will be evaluated with respect to grade and relationship to treatment, using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.03.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab, Chemotherapy, Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On day 1 of each 21 day cycle, participants will be administered Pembrolizumab 200mg (IV); Chemotherapy including Paclitaxel 175mg/m2 or 135 mg/m2 (IV), and Cisplatin 50mg/m2 (IV) or Carboplatin AUC 5; and Bevacizumab 15mg/kg (IV).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>IV</description>
    <arm_group_label>Pembrolizumab, Chemotherapy, Bevacizumab</arm_group_label>
    <other_name>MK-3475</other_name>
    <other_name>Keytruda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Administered intravenously (IV) on day 1</description>
    <arm_group_label>Pembrolizumab, Chemotherapy, Bevacizumab</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Administered intravenously (IV) on day 1</description>
    <arm_group_label>Pembrolizumab, Chemotherapy, Bevacizumab</arm_group_label>
    <other_name>Platinol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Administered intravenously (IV) on day 1</description>
    <arm_group_label>Pembrolizumab, Chemotherapy, Bevacizumab</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Administered intravenously (IV) on day 1</description>
    <arm_group_label>Pembrolizumab, Chemotherapy, Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must have histologically confirmed recurrent, persistent or metastatic&#xD;
             (primary stage IVB) squamous cell carcinoma, adenosquamous carcinoma or adenocarcinoma&#xD;
             of the cervix that is not amenable to curative treatment with surgery and/or radiation&#xD;
             therapy.&#xD;
&#xD;
          2. All patients must have measurable disease as defined by Response Evaluation Criteria&#xD;
             In Solid Tumors (RECIST) 1.1.&#xD;
&#xD;
          3. Patients must have recovered from effects of recent surgery or radiotherapy or&#xD;
             chemoradiotherapy.&#xD;
&#xD;
          4. Patients should be free of active infections requiring antibiotics (with the exception&#xD;
             of uncomplicated urinary tract infection).&#xD;
&#xD;
          5. Tissue from an archival sample or newly obtained core or excisional biopsy of a tumor&#xD;
             lesion within 6 weeks confirming diagnosis.&#xD;
&#xD;
          6. Age ≥ 18 years&#xD;
&#xD;
          7. Life expectancy &gt; 3 months&#xD;
&#xD;
          8. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1&#xD;
&#xD;
          9. Patients must have normal organ and marrow function as defined below:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥1,500 /mcL&#xD;
&#xD;
               -  Platelets ≥ 100,000 / mcL&#xD;
&#xD;
               -  Hemoglobin ≥ 8 g/dL or ≥ 5.6 mmol/L without transfusion or erythropoietin (EPO)&#xD;
                  dependency&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 X upper limit of normal (ULN) OR Measured or calculated a&#xD;
                  creatinine clearance (GFR can also be used in place of creatinine or CrCl) ≥ 60&#xD;
                  mL/min for subject with creatinine levels &gt; 1.5 X institutional ULN. Creatinine&#xD;
                  clearance should be calculated per institutional standard.&#xD;
&#xD;
               -  Serum total bilirubin ≤ 1.5 X ULN OR Direct bilirubin ≤ ULN for subjects with&#xD;
                  total bilirubin levels &gt; 1.5 ULN&#xD;
&#xD;
               -  Aspartate transaminase (AST) (SGOT) and alanine transaminase (ALT) (SGPT) ≤ 2.5 X&#xD;
                  ULN OR ≤ 5 X ULN for subjects with liver metastases&#xD;
&#xD;
               -  Albumin ≥ 2.5 mg/dL&#xD;
&#xD;
               -  International Normalized Ratio (INR) or Prothrombin Time (PT) ≤ 1.5 X ULN unless&#xD;
                  subject is receiving anticoagulant therapy as long as PT or PTT is within&#xD;
                  therapeutic range of intended use of anticoagulants.&#xD;
&#xD;
               -  Activated Partial Thromboplastin Time (aPTT) ≤ 1.5 X ULN unless subject is&#xD;
                  receiving anticoagulant therapy as long as PT or PTT is within therapeutic range&#xD;
                  of intended use of anticoagulants.&#xD;
&#xD;
         10. Negative urine or serum pregnancy ≤72 hours (i.e. 3 days) prior to receiving the first&#xD;
             dose of study medication if not surgically sterilized. If the urine test is positive&#xD;
             or cannot be confirmed as negative, a serum pregnancy test will be required.&#xD;
&#xD;
         11. Female subjects of childbearing potential (have not been surgically sterilized or have&#xD;
             not been without menses for &gt;1 year) should be willing to use 2 methods of birth&#xD;
             control at the same time or be surgically sterile, or abstain from heterosexual&#xD;
             activity&#xD;
&#xD;
         12. Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with a history of other invasive malignancies, with the exception of&#xD;
             nonmelanoma skin cancer, are ineligible if there is any evidence of other malignancy&#xD;
             being present within the last 5 years.&#xD;
&#xD;
          2. Patients who have had prior chemotherapy except when used concurrently with radiation&#xD;
             therapy.&#xD;
&#xD;
          3. Patients who have received prior radiotherapy to any portion of the abdominal cavity&#xD;
             or pelvis other than for the treatment of cervical cancer within the last 5 years are&#xD;
             excluded. Prior radiation for localized cancer of the breast, head and neck, or skin&#xD;
             is permitted provided that it was completed more than 3 years prior to registration,&#xD;
             and the patient remains free of recurrent or metastatic disease.&#xD;
&#xD;
          4. Patients with an ECOG performance status of 2, 3 or 4.&#xD;
&#xD;
          5. Has received prior therapy with an anti-PD1, anti-PDL1, or anti-PDL2 agent.&#xD;
&#xD;
          6. Patients with known active central nervous system (CNS) metastases and/or&#xD;
             carcinomatous meningitis.&#xD;
&#xD;
          7. Patients with a known sensitivity to humanized antibodies or sensitivity attributed to&#xD;
             compounds of similar chemical or biologic composition to platinum based chemotherapy&#xD;
             or paclitaxel (not responsive to traditional desensitization procedures).&#xD;
&#xD;
          8. Patients with a known history of human immunodeficiency virus (HIV), active bacillus&#xD;
             tuberculosis (TB), or have received a live virus vaccine within 30 days prior to the&#xD;
             first dose of study treatment.&#xD;
&#xD;
          9. Known psychiatric or substance abuse disorders that would interfere with cooperation&#xD;
             with requirements of the study&#xD;
&#xD;
         10. Has active autoimmune disease that has required systemic treatment in the past two&#xD;
             years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive&#xD;
             drugs). Replacement therapy (i.e. thyroxine, insulin, or physiologic corticosteroid&#xD;
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a&#xD;
             form of systemic treatment.&#xD;
&#xD;
         11. History of non-infectious pneumonitis that required steroids, evidence of interstitial&#xD;
             lung disease or active, non-infectious pneumonitis, or history of pneumonitis&#xD;
             requiring treatment.&#xD;
&#xD;
         12. Is pregnant or breastfeeding or expecting to conceive within the projected duration of&#xD;
             the study, starting with the pre-screening or screening visit through 120 days after&#xD;
             the last dose of study treatment.&#xD;
&#xD;
         13. Known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA&#xD;
             [qualitative] is detected).&#xD;
&#xD;
         14. Received live vaccine within 30 days prior to the first dose of study treatment. Note:&#xD;
&#xD;
             Seasonal influenza vaccines for injection are generally inactivated flu vaccines and&#xD;
             are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live&#xD;
             attenuated vaccines, and are not allowed.&#xD;
&#xD;
         15. Patient with known hypersensitivity to pembrolizumab or any of its excipients (active&#xD;
             ingredients).&#xD;
&#xD;
         16. Patient receiving concurrent additional biologic therapy.&#xD;
&#xD;
         17. History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to cisplatin and/or paclitaxel not responsive to traditional&#xD;
             desensitization procedures.&#xD;
&#xD;
         18. Any other serious medical or psychiatric illness/condition, in the judgment of the&#xD;
             Investigator(s), is likely to interfere or limit compliance with study&#xD;
             requirements/treatment.&#xD;
&#xD;
         19. Patients who are adults and unable to consent, who are not yet adults, pregnant and&#xD;
             nursing women, and prisoners are ineligible.&#xD;
&#xD;
         20. Any other serious medical or psychiatric illness/condition likely in the judgment of&#xD;
             the Investigator(s) to interfere or limit compliance with study&#xD;
             requirements/treatment.&#xD;
&#xD;
         21. Has an active infection requiring systemic therapy.&#xD;
&#xD;
         22. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any&#xD;
             other form of immunosuppressive therapy within 7 days prior to planned first dose of&#xD;
             the study. The use of physiological doses of corticosteroids may be approved after&#xD;
             consultation with the PI.&#xD;
&#xD;
         23. Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or&#xD;
             child who is an investigational site or sponsor staff directly involved with this&#xD;
             trial, unless prospective institutional review board (IRB) approval (by chair or&#xD;
             designee) is given, allowing exception to this criterion.&#xD;
&#xD;
         24. Thromboembolism (either arterial or venous) within 6 weeks of initiation of treatment.&#xD;
&#xD;
         25. Have significant cardiovascular disease, such as New York Heart Association cardiac&#xD;
             disease (Class II or greater), myocardial infarction, or cerebrovascular accident&#xD;
             within 3 months prior to initiation of study treatment, unstable arrhythmias, or&#xD;
             unstable angina. Patients with known coronary artery disease, congestive heart failure&#xD;
             not meeting the above criteria, or left ventricular ejection fraction &lt;50% must be on&#xD;
             a stable medical regimen that is optimized in the opinion of the treating physician,&#xD;
             in consultation with a cardiologist if appropriate.&#xD;
&#xD;
         26. Undergo major surgical procedure within 28 days prior to first bevacizumab dose or&#xD;
             anticipation of the need for a major surgical procedure during the course of the&#xD;
             study.&#xD;
&#xD;
         27. Have proteinuria, as demonstrated by urine dipstick or &gt;1.0g of protein in a urine&#xD;
             protein-to-creatinine ratio and/or 24hr urine collection. All patients with ≥2+&#xD;
             protein on dipstick urinalysis at baseline must undergo a urine-to-protein ration&#xD;
             and/or 24hr urine collection and demonstrate &lt;1.0g of protein&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marilyn Huang, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marilyn Huang, MD, MS</last_name>
    <phone>305-243-2233</phone>
    <email>m.huang@med.miami.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marilyn Huang, MD, MS</last_name>
      <phone>305-243-2233</phone>
      <email>m.huang@med.miami.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 5, 2017</study_first_submitted>
  <study_first_submitted_qc>December 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2017</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Marilyn Huang, MD, MS</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Recurrent Cervical Cancer</keyword>
  <keyword>Persistent Cervical Cancer</keyword>
  <keyword>Metastatic Cervical Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

